Webcast CME

Advancing Care Delivery to Improve Cardiovascular and Renal Outcomes in High-Risk Patients with Type 2 Diabetes

Evidence-based Management of T2D with ASCVD, CKD, or HF

Print this Content

Release date: March 31, 2022
Expiration date: March 31, 2023

Estimated Time of Completion: 30 minutes

Description

Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. The Advancing Care Delivery to Improve Cardiovascular and Renal Outcomes in High-Risk Patients with Type 2 Diabetes online series will  increase health care professional’s level of confidence in assessing their patients’ profile and needs, improve their knowledge of the available T2D treatment options (to include novel agents), and enhance their ability to educate, inform, and treat at-risk patients by pursuing the most effective (and guideline recommended) treatment plans.

Watch SGLT-2 Inhibitors webcast for a review of the risks and benefits of SGLT-2 inhibitors and how they can be incorporated into existing diabetes regimens for patients. . Using current evidence-based data, American Diabetes Association (ADA) guidelines regarding the use of SGLT-2 inhibitors will be discussed.

Learning Objectives

  1. Identify indications and contraindications for GLP-1 RA and SGLT2i therapy
  2. Summarize the literature on cardiovascular disease and CKD reduction with GLP-1 RA and CVD and CKD protection with SGLT2i
  3. Review how to prescribe common GLP-1 RA and SGLT2i agents
  4. Recognize and manage adverse effects from GLP-1 RA and SGLT2i medications

Target Audience

The online series is designed for primary care and internal medicine practitioners, endocrinologists, cardiologists, nephrologists, allied health professionals, and those who treat patients with Type 2 Diabetes.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director

Vinni Makin, MD, FACE
Director of Endocrinology (East)
Department of Endocrinology
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, OH

Kevin M. Pantalone, DO, ECNU, FACE
Staff Endocrinologist
Director of Clinical Research
Department of Endocrinology
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, OH

Pratibha PR Rao, MD, MPH
Quality Improvement Officer
Department of Endocrinology
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:



Kevin M. Pantalone, DO
Astra Zeneca Consulting
Teaching and Speaking
Eli Lilly Consulting
Merck & Co, Inc. Consulting
Research support
Teaching and Speaking
Novo Nordisk, Inc. Consulting
Research Support
Teaching and Speaking
Sanofi Aventis Consulting
Corcept Consulting
Teaching and Speaking
Bayer Consulting
Research / Independent Contractor
Diasome, Inc. Consulting

The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:

Vinni Makin, MD
Pratibha PR Rao, MD, MPH


Acknowledgement

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of the Internet Enduring activity from:
Lilly USA, LLC
Merck Sharp & Dohme Corp

 


This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and Endocrinology and Metabolism Institute.